Combination immunotherapy in chemotherapy in gastric cancer

On the basis of the results of the CheckMate 649 trial 1 Janjigian YY Shitara K Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021; 398: 27-40 Summary Full Text Full Text PDF PubMed Scopus (959) Google Scholar and the KEYNOTE-859 trial, 2 Rha SY Wyrwicz L Weber PE et al. KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: outcomes in the protocol-specified PD-L1-selected populations. Proc Am Soc Clin Oncol. 2023; 41 (abstr).4014 PubMed Google Scholar the standard regimen for patients with advanced, untreated, HER2-negative gastric cancer is doublet chemotherapy combined with an immune checkpoint inhibitor. However, the prognosis for advanced gastric cancer remains poor, particularly for patients with low PD-L1 expression. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialRegorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer. A randomised, phase 3 clinical trial is planned. Full-Text PDF